Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperthermia and CIK Immunotherapy in Abdominal and Pelvic Malignancies
NCT03757858Phase 2Completed
- Sponsor
- Capital Medical University
- Start
- Mar 2018
- Primary completion
- Dec 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of unmodified CIK in Abdominal cancer and Pelvic cancer (4 arms), sponsored by Capital Medical University. Primary endpoints: Safety (adverse events) at 12 months and Objective Response Rate at 6 months. Started Mar 2018; status: completed.
02
Drugs
unmodified CIK
03
Conditions
Abdominal cancerPelvic cancer
Beyond the preview
Go deeper on NCT03757858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757858.